乳腺癌组织及间质浸润淋巴细胞中PD-L1的表达及其意义

发布时间：2018-12-21 20:14

【摘要】：目的探讨程序性死亡配体-1(programmed death ligand-1,PD-L1)在乳腺癌组织及间质浸润淋巴细胞(stromal tumor-infiltrating lymphocyte,sTIL)中的表达及其与临床病理特征的关系。方法收集68例乳腺非特殊性浸润性癌,采用免疫组化EliVision两步法检测PD-L1蛋白表达,并分析其与免疫组化亚型及临床病理特征的关系。结果乳腺肿瘤细胞中PD-L1总阳性率为35.3%,尤其在三阴型乳腺癌肿瘤细胞中的阳性率最高,在管腔型、HER-2过表达型及三阴型乳腺癌肿瘤细胞中的阳性率分别为16.1%、37.5%、61.9%,差异有统计学意义。PD-L1在sTIL中的总阳性率为51.5%,且在三阴型乳腺癌中最高,阳性率为81.0%;PD-L1在管腔型、HER-2过表达型及三阴型乳腺癌sTIL中的表达差异具有统计学意义。PD-L1在乳腺癌与sTIL中的表达呈正相关。结论 PD-L1在三阴型乳腺癌中表达明显高于其他类型乳腺癌,阻断PD-L1/PD-1信号通路,有望成为乳腺癌尤其是三阴型乳腺癌免疫治疗的新策略。
[Abstract]:Objective to investigate the expression of programmed death ligand 1 (programmed death ligand-1,PD-L1 in breast cancer tissues and interstitial infiltrating lymphocytes (stromal tumor-infiltrating lymphocyte,sTIL) and its relationship with clinicopathological features. Methods 68 cases of nonspecific invasive breast carcinoma were collected. The expression of PD-L1 protein was detected by immunohistochemical EliVision two-step method, and its relationship with immunohistochemical subtypes and clinicopathological features was analyzed. Results the total positive rate of PD-L1 in breast cancer cells was 35.3g, especially the highest positive rate in tri-negative breast cancer cells, and the positive rate was in lumen type. The positive rates of HER-2 overexpression type and triple negative type breast cancer cell were 16.1and 37.5 respectively, the difference was statistically significant. The total positive rate of PD-L1 in sTIL was 51.5%. The highest positive rate was 81.0 in the three-negative breast cancer. There was a significant difference in the expression of PD-L1 in lumen type, HER-2 overexpression type and triple negative type breast cancer sTIL. The expression of PD-L1 in breast cancer was positively correlated with sTIL expression. Conclusion the expression of PD-L1 in triple negative breast cancer is significantly higher than that in other types of breast cancer. Blocking the PD-L1/PD-1 signaling pathway may be a new strategy of immunotherapy for breast cancer, especially for triple negative breast cancer.
【作者单位】：安徽省池州市人民医院病理科;
【分类号】：R737.9

【相似文献】